Advertisements


Vertex"s Third Cystic Fibrosis Treatment Gets FDA Approval

Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment. .....»»

Category: personnelSource: nytFeb 13th, 2018

The Wall Street Journal: Vertex to seek approval of new cystic-fibrosis drug

Vertex Pharmaceuticals Inc. said it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients’ lung function in late-stage studies......»»

Category: topSource: marketwatchMar 28th, 2017

Vertex says non-opioid pain drug hits mark in study

Vertex Pharmaceuticals has unveiled promising findings from a study of one of its experimental drugs — only this time, the treatment doesn’t target cystic fibrosis. Boston-based Vertex (Nasdaq: VRTX), which largely focuses on the lung disorder,.....»»

Category: topSource: bizjournalsFeb 14th, 2018

Vertex scores FDA approval for new cystic fibrosis drug

Vertex Pharmaceuticals said Monday that the FDA has approved its third drug for cystic fibrosis, lifting shares of the Boston-based company. Vertex (Nasdaq: VRTX) said the drug — a combination of Kalydeco, which was approved in 2012, and a new medic.....»»

Category: topSource: bizjournalsFeb 12th, 2018

3 Stocks to Watch on Wednesday: Vertex Pharmaceuticals Incorporated (VRTX), CSX Corporation (CSX) and International Business Machines Corp. (IBM)

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals (VRTX) soars on cystic fibrosis treatment data, CSX Corporation (CSX) falls on a restructuri.....»»

Category: topSource: investorplaceJul 19th, 2017

The Ratings Game: Vertex Pharma shares soar 21% as company ups its cystic fibrosis offerings

Wall Street analysts were unusually impressed by the Tuesday results from a trial of a cystic fibrosis treatment......»»

Category: topSource: marketwatchMar 29th, 2017

Why This Key Analyst Has a Mixed View of Vertex’s Win

Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older......»»

Category: blogSource: 247wallstMar 29th, 2017

The Ratings Game: Vertex Pharma shares soar 23% as company ups its cystic fibrosis offerings

Wall Street analysts were unusually impressed by the Tuesday results from a trial of a cystic fibrosis treatment......»»

Category: topSource: marketwatchMar 29th, 2017

A cystic fibrosis drug succeeded in a late-stage trial — and the company"s stock is soaring (VRTX)

Vertex PharmaceuticalsBy March 28 (Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrate.....»»

Category: topSource: businessinsiderMar 29th, 2017

Vertex gains nearly $4B in market cap on positive cystic fibrosis data

Shares of Vertex Pharmaceuticals surged Tuesday evening after the Boston drugmaker reported positive results from two closely watched trials of a combination treatment for cystic fibrosis, moving the company closer to its goal of treating nearly al.....»»

Category: topSource: bizjournalsMar 28th, 2017

Concert Pharma shares rally 34% on news Vertex to pay up to $250 million for cystic fibrosis drug

Shares of Concert Pharmaceuticals Inc. rallied 34% premarket Monday, after the company said Vertex Pharmaceuticals Inc. is buying its cystic fibrosis treatment CTP-656 and other asset.....»»

Category: topSource: marketwatchMar 6th, 2017

Vertex Orkambi"s Label Expanded in U.S., Outlook Revised

Vertex (VRTX) announced that the FDA has approved the use of its cystic fibrosis drug, Orkambi, for the treatment of patients aged 6-11 years. Vertex Pharmaceuticals Incorporated VRTX announced that its cystic fibrosis (CF) drug, Orkambi, was a.....»»

Category: topSource: zacksSep 30th, 2016

How Proteostasis" Recent Data In Cystic Fibrosis Compares To Vertex"s

How Proteostasis" Recent Data In Cystic Fibrosis Compares To Vertex"s.....»»

Category: topSource: seekingalphaFeb 8th, 2018

Brainstorm Health: Right to Try, Alzheimer’s Blood Test, Vertex Cystic Fibrosis Trials

Brainstorm Health Daily: February 1, 2018 Hello, readers! This is Sy. President Donald Trump on Tuesday d.....»»

Category: europeSource: fortuneFeb 1st, 2018

Will These 2 Large-Cap Biotechs Be on Investor Radar in "18?

Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Al.....»»

Category: personnelSource: nytJan 3rd, 2018

Vertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential Ahead

Vertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential Ahead.....»»

Category: topSource: seekingalphaOct 10th, 2017

Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis dr.....»»

Category: topSource: zacksJul 21st, 2017

Vertex Wins Big in Mid-Stage Cystic Fibrosis Trial

Shares of Vertex Pharmaceuticals shot up after the company announced dramatic results from its early and mid-stage trials in cystic fibrosis. The stock pushed to an all-time high on the back of these........»»

Category: blogSource: 247wallstJul 19th, 2017

Vertex Eyes The Treble In Cystic Fibrosis

Vertex Eyes The Treble In Cystic Fibrosis.....»»

Category: topSource: seekingalphaJul 19th, 2017

Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today

Vertex's cystic fibrosis franchise keeps rolling with yet another string of positive clinical data readouts......»»

Category: topSource: foxnewsJul 19th, 2017

A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals

Following strong Phase I and II data on Tuesday from three different triple combo regimens for cystic fibrosis, shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rocketed 30 percent Wednesday to $162.07. Latest Ratings f.....»»

Category: blogSource: benzingaJul 19th, 2017